Cancer Tubulin Inhibitors
Cancer Tubulin Inhibitors market is segmented by Type and by Application. Players, stakeholders, ... Read More
Proto-Oncogene Drgu market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Proto-Oncogene Drgu market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Axitinib (Inlyta)
Ponatinib (Iclusig)
Imatinib (Gleevec)
Sunitinib (Sutent)
Pazopanib (Votrient)
Dabrafenib (Tafinlar)
Vandetanib (Caprelsa)
Vemurafenib (Zelboraf)
Cabozantinib (Cabometyx and Cometriq)
Sorafenib (Nexavar)
Segment by Application
Clinic
Hospital
Others
By Company
ARIAD Pharmaceuticals
AstraZeneca
Bayer Healthcare
Bristol-Myers Squibb
ChemGenex Pharmaceuticals
Dexa Medica
Eisai Pharmaceuticals
Exelixis
GlaxoSmithKline
Novartis
Onyx Pharmaceuticals
Plexxikon
Pfizer
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Cancer Tubulin Inhibitors market is segmented by Type and by Application. Players, stakeholders, ... Read More
Cancer mTOR Inhibitors market is segmented by Type and by Application. Players, stakeholders, and ... Read More
Sample Preparation Products for Next Generation Sequencing market is segmented by Type and by App ... Read More
Library Preparation and Target Enrichment for Next Generation Sequencing Product market is segmen ... Read More